Home Cart Sign in  
Chemical Structure| 510-30-5 Chemical Structure| 510-30-5

Structure of Echinocystic acid
CAS No.: 510-30-5

Chemical Structure| 510-30-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Echinocystic Acid is a natural triterpene acid derivative possessing anti inflammatory property.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Echinocystic acid

CAS No. :510-30-5
Formula : C30H48O4
M.W : 472.70
SMILES Code : OC([C@]12[C@](CC(C)(CC2)C)([H])C3=CC[C@@]([C@@]4([C@@](C(C)([C@H](CC4)O)C)([H])CC5)C)([H])[C@]5(C)[C@@]3(C[C@H]1O)C)=O
MDL No. :MFCD00017295
InChI Key :YKOPWPOFWMYZJZ-PRIAQAIDSA-N
Pubchem ID :73309

Safety of Echinocystic acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SHSY5Y cells 16 μM Conditioned medium treatment EA alleviated microglia-mediated neuron death in SHSY5Y cells Front Pharmacol. 2022 Jan 19;12:787771
SN4741 cells 16 μM Conditioned medium treatment EA alleviated microglia-mediated neuron death in SN4741 cells Front Pharmacol. 2022 Jan 19;12:787771
BV2 cells 16 μM 1 h pretreatment followed by LPS stimulation for 12 or 24 h EA inhibited the mRNA and protein expression of pro-inflammatory mediators (iNOS, COX-2, IL-6, and TNF-α) in LPS-exposed BV2 cells Front Pharmacol. 2022 Jan 19;12:787771
primary cortical neurons 5, 10, 15, 20 μM 24 hours To evaluate the protective effect of EA on oxygen-glucose deprivation/reperfusion (OGD/R)-induced neuronal injury. Results showed that EA significantly increased neuronal survival rate, reduced cell death and ROS levels. Front Pharmacol. 2023 Feb 9;14:1103265
Leghorn male hepatoma cells (LMHs) 10 μM 24 hours To evaluate the anti-steatotic effects of EA in vitro. The results showed that EA significantly reduced intracellular TG and TC levels and decreased lipid deposition. Poult Sci. 2025 Apr;104(4):104981
Jurkat cells 20 µM 48 hours Evaluate the effect of Echinocystic acid on Jurkat cell viability, showing no effect. Molecules. 2021 Feb 5;26(4):848
A549 cells 100 µM 7 hours Evaluate the effect of Echinocystic acid on the viability of A549 cells, showing significant reduction in cell viability at 100 µM Int J Mol Sci. 2024 May 30;25(11):6026

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL6 mice MPTP-induced Parkinson's disease model Intragastric administration 5 mg/kg Once daily for 17 days EA improved MPTP-induced weight loss and behavioral impairment, inhibited dopaminergic neuron damage and inflammation in the midbrain Front Pharmacol. 2022 Jan 19;12:787771
Neonatal C57BL/6 mice Hypoxic-ischemic brain damage (HIBD) model Intraperitoneal injection 100 mg/kg Administered immediately, observed up to 24 hours or 3 weeks To evaluate the protective effect of EA on HIBD. Results showed that EA significantly reduced cerebral infarction, attenuated neuronal injury, and improved brain atrophy and long-term neurobehavioral deficits. Front Pharmacol. 2023 Feb 9;14:1103265
Male K90 broiler chickens High-fat diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) model Dietary supplementation 25 mg/kg and 50 mg/kg 21 days To investigate the effects of EA on abdominal fat deposition and fatty liver disease in broiler chickens. The results showed that EA significantly reduced abdominal fat deposition, decreased liver and serum levels of TG, TC, and LDL-C, and increased HDL-C levels. Additionally, EA altered the composition of the gut microbiota, particularly by decreasing the ratio of Firmicutes to Bacteroidetes. Poult Sci. 2025 Apr;104(4):104981
Sprague-Dawley rats Ovariectomy-induced osteoporotic rat model Intragastric administration 1, 5, and 15 mg/kg/day Once daily for 12 weeks To evaluate the protective effect of EA on ovariectomy-induced osteoporosis. Results showed that administration of EA (5 or 15 mg/kg/day) prevented lower levels of maximum stress and Young’s modulus of femur induced by OVX, recovered bone metabolic biomarkers levels, improved trabecular architecture, and decreased serum levels of IL-1β and TNF-α in OVX rats. PLoS One. 2015 Aug 28;10(8):e0136572
Sprague Dawley rats Hyperhomocysteinemia model Gastric gavage 20 mg/kg and 40 mg/kg Once daily for 8 weeks To investigate the effects of EA on aortic morphology, plasma Hcy levels, and the expression of NF-κB and CYP1A1 in a rat model of hyperhomocysteinemia. Results showed that EA significantly reduced plasma Hcy levels, decreased NF-κB and CYP1A1 expression, and had a protective effect on vascular endothelial cells. Exp Ther Med. 2017 Nov;14(5):4174-4180

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.12mL

0.42mL

0.21mL

10.58mL

2.12mL

1.06mL

21.16mL

4.23mL

2.12mL

References

 

Historical Records

Categories